Liu, Yang

CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses

Chen, G.-Y., Tang, J., Zheng, P., & Liu, Y. (2009) · Science

Immune Response and InflammationInflammation biomarkers and pathways

Cited by 786

mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells

Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling

Hematopoietic Stem Cell TransplantationGenetics, Aging, and Longevity in Model Organisms

Cited by 680

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 577

Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies

Wang, Y., Liu, Y., Malek, S. N., Zheng, P., & Liu, Y. (2011) · Cell stem cell

Cancer, Hypoxia, and MetabolismCancer Cells and Metastasis

Cited by 410

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 328

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 151

CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns

Liu, Y., Chen, G.-Y., & Zheng, P. (2009) · Trends in Immunology

Immune Response and InflammationInflammation biomarkers and pathways

Cited by 147

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Du, X., Liu, M., Su, J., Zhang, P., Tang, F., Ye, P., Devenport, M., Wang, X., Zhang, Y., Liu, Y., et al. (2018) · Cell Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 123

Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity

Chen, G.-Y., Brown, N. K., Zheng, P., & Liu, Y. (2014) · Glycobiology

Glycosylation and Glycoproteins ResearchImmune Response and Inflammation

Cited by 90

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

Wang, Y., Liu, Y., Tang, F., Bernot, K. M., Schore, R., Marcucci, G., Caligiuri, M. A., Zheng, P., & Liu, Y. (2014) · Blood

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 69

Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer

Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine

Cancer, Hypoxia, and MetabolismNanoparticle-Based Drug Delivery

Cited by 44

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin

Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 38

Sialoside-based pattern recognitions discriminating infections from tissue injuries

Liu, Y., Chen, G.-Y., & Zheng, P. (2011) · Current Opinion in Immunology

Immune Response and InflammationGlycosylation and Glycoproteins Research

Cited by 28